Welcome to our dedicated page for Elanco Animal Health SEC filings (Ticker: ELAN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Elanco Animal Health filings document the disclosures of a public animal health company focused on products for farm animals and pets. The record includes Form 8-K reports on operating results, clinical or regulatory matters, capital-structure updates, credit-facility amendments, investor presentations, and restructuring-related exit or disposal activities.
Elanco's proxy materials describe board composition, shareholder voting matters, executive compensation, equity awards, and governance practices. Its filings also provide formal disclosure around material events, financial reporting, and the capital arrangements that support the company's global animal health operations.
Simmons Jeffrey N reported acquisition or exercise transactions in this Form 4 filing.
Elanco Animal Health Inc’s president, CEO and director Jeffrey N. Simmons received a grant of 113.8973 deferred stock units on July 10, 2026, referenced at $24.8200 per unit. Following this award, he holds 24,770.9021 deferred stock units directly.
Each deferred stock unit represents the right to receive one share of common stock or the cash equivalent and will settle in cash or shares after termination of employment, or in a specified future year, under the Executive Deferral and Stock Match Plan.
VanHimbergen Robert M reported acquisition or exercise transactions in this Form 4 filing.
Elanco Animal Health’s EVP and CFO, Robert M. VanHimbergen, received a grant of 7.9380 deferred stock units on 2026-07-10 at a reference value of $24.8200 per unit. Each unit represents the right to receive one share of common stock or the cash equivalent under the Executive Deferral and Stock Match Plan and will settle after employment ends or in a specified future year. Following this award, he holds 116.7886 deferred stock units directly.
Modi Rajeev A. reported acquisition or exercise transactions in this Form 4 filing.
Elanco Animal Health Inc company officer Rajeev A. Modi received a grant of 59.5056 deferred stock units on July 10, 2026 at a reference price of $24.82 per unit. Each unit represents the right to one share of common stock or the cash equivalent and will settle after employment ends or in a specified future year under the Executive Deferral and Stock Match Plan. Following this award, Modi directly holds 9,582.6368 deferred stock units.
Dimensional Fund Advisors LP reports beneficial ownership of 25,417,271 shares of Elanco Animal Health Inc common stock, representing 5.1% of the outstanding class as of 06/30/2026. These shares are held across various investment companies, commingled funds, group trusts and separate accounts it advises.
Dimensional has 25,063,534 shares with sole voting power and 25,417,271 shares with sole dispositive power, with no shared voting or dispositive authority. The underlying Funds have the right to receive dividends and sale proceeds, and to Dimensional’s knowledge no single Fund holds more than 5% of the class. Dimensional disclaims beneficial ownership of all such securities outside Section 13(d) reporting purposes.
Elanco Animal Health EVP and CFO Robert M. VanHimbergen reported a tax-related share disposition. On this Form 4, 15,336 shares of Common Stock were used at $24.64 per share to satisfy tax obligations by delivering shares to the issuer. After this tax-withholding disposition, he directly holds 133,316 shares of Elanco common stock, indicating the event is compensation- and tax-driven rather than an open-market trade.
Elanco Animal Health executive David S. Kinard received a grant of employee stock options, giving him rights to buy 25,620 shares of common stock at an exercise price of $24.09 per share. These options vest in three equal installments on March 1, 2027, March 1, 2028, and March 1, 2029, and expire on July 1, 2036. Following this grant, Kinard holds 25,620 stock options directly.
Anand Kapila K reported acquisition or exercise transactions in this Form 4 filing.
Elanco Animal Health director K. Anand reported receiving 584.1121 Deferred Stock Units on June 30, 2026. These units were issued at an implied price of $24.61 per unit by deferring her director cash retainer into the company’s Directors’ Deferral Plan.
Each Deferred Stock Unit is the economic equivalent of one share of Elanco common stock and will be settled in stock when she leaves the Board. Following this compensation-related award, Anand holds a total of 10,079.5639 Deferred Stock Units directly.
Modi Rajeev A. reported acquisition or exercise transactions in this Form 4 filing.
Elanco Animal Health reported that executive Rajeev A. Modi received a grant of 60.1111 deferred stock units on June 26, 2026, each tied to Company common stock at a reference price of $24.57 per unit. After this award, he holds 9,523.1312 deferred stock units in total.
Each deferred stock unit represents the right to receive either one share of Elanco common stock or the cash equivalent. These units are scheduled to settle in cash or shares after employment ends or in a specified future year under the Executive Deferral and Stock Match Plan.
Elanco Animal Health Inc reported that President and CEO Jeffrey N. Simmons received a grant of deferred stock units under a compensation plan. The award covers 115.0562 deferred stock units, each linked to one share of Elanco common stock or its cash equivalent at a reference value of $24.57 per unit.
Following this award, Simmons holds a total of 24,657.0048 deferred stock units directly. These units are designed to settle in cash or company shares after his employment ends or in a specified future year, in line with the Executive Deferral and Stock Match Plan, making this a routine, non-market, compensation-related acquisition rather than an open-market purchase.
VanHimbergen Robert M reported acquisition or exercise transactions in this Form 4 filing.
Elanco Animal Health EVP and CFO Robert M. VanHimbergen received a grant of 8.0187 deferred stock units tied to Elanco common stock at a reference price of $24.57 per unit. Following this award, he holds 108.8506 deferred stock units, which will settle in cash or shares after employment ends or in a specified future year.